Regentis Biomaterials Ltd.
New York Stock Exchange AmericanRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Regentis Biomaterials Ltd. (RGNT) is a regenerative medicine company focused on developing innovative tissue repair solutions using degradable hydrogel implants to regenerate damaged or diseased orthopedic tissue, including inflamed cartilage and bone. The company offers products and services based on its proprietary Gelrin platform, a unique hydrogel matrix composed of polyethylene glycol diacrylate and denatured fibrinogen; its lead product candidate, GelrinC, comprises a cell-free, off-the-shelf hydrogel that surgeons cure into an implant in the knee to treat painful articular cartilage injuries, providing a simple, cost-effective procedure with potential for sustained pain relief, functional improvement, and quick patient recovery. GelrinC holds a CE mark as a medical device in Europe since 2017 and is advancing through pivotal clinical trials in the United States and Europe toward FDA premarket approval (PMA), supported by 34 granted patents and three pending applications covering compositions, delivery devices, surgical techniques, and manufacturing processes across numerous countries; manufacturing adheres to GMP and ISO 13485 standards. Founded in 2004 and headquartered at 60 Medinat Hayehudim in Herzliya, Israel, the company targets orthopedic markets, particularly unmet needs in knee cartilage repair, with operations spanning clinical development in the United States and Europe and planned commercialization partnerships in Europe. Regentis Biomaterials operates as an Israel-incorporated entity with approximately three employees, led by CEO Dr. Eli Hazum, and maintains a privately held structure backed by investors including Medica Venture Partners, SCP Vitalife, Royal DSM Ventures, Haisco Pharmaceutical Group, and others. In recent developments, Regentis Biomaterials filed a registration statement on Form F-1 with the SEC in March 2025, amending it multiple times through July 2025 to pursue an initial public offering of 1.0 million shares priced at $10.00-$12.00 on the NYSE American, aiming to raise $11.0 million with an expected trading commencement around December 2025. The company extended certain loan agreements through November 2025 to support ongoing operations and clinical efforts, while progressing its pivotal trial for GelrinC, which has treated over 47 of 80 required patients as of prior updates. Previously, Regentis announced a $10.0 million Series C funding round and pursued a business combination with OceanTech Acquisitions I Corp. in 2023, though it shifted to a direct IPO strategy; no revenue has been generated to date, with focus on accelerating FDA PMA submission and European market entry via strategic alliances.
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate
Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon
Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%
Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update
Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair
Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method
Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation
Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC
U.S. IPO Weekly Recap: December Kicks Off With 3 Notable Launches In A Week With 7 SPACs
Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering
Regentis Biomaterials Ltd. Announces Pricing of Initial Public Offering